Neuropsychopharmacology of Opiate Dependence

  • Rafael Maldonado
  • Luis Stinus
  • George F. Koob
Part of the Neuroscience Intelligence Unit book series (NIU.LANDES)

Abstract

Opiate drugs are powerful and widely-used analgesic agents. However, their chronic administration is limited by the development of tolerance, indicated by a lowered responsiveness to the drug, coupled with dependence which is evidenced by a heightened responsiveness to opiate antagonists and disturbances upon withdrawal of drugs. These phenomena result from cellular and molecular mechanisms, considered as adaptive processes that develop in response to repeated administration of the drugs, and persist long after the drug has been cleared from the central nervous system. Two types of mechanisms have been proposed to account for these processes: a within-adaptive system and/or a between-adaptive system.1−4

Keywords

Attenuation Dopamine Cocaine Catecholamine Neuroblastoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715–723.PubMedCrossRefGoogle Scholar
  2. 2.
    Koob GF, Stinus L, Le Moal M et al. Opponent process theory of motivation: Neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev 1989; 13: 135–140.PubMedCrossRefGoogle Scholar
  3. 3.
    Solomon RL. The opponent process theory of acquired motivation. Am Psychol 1980; 35: 691–712.PubMedCrossRefGoogle Scholar
  4. 4.
    Solomon RL. Acquired motivation and affective opponent processes. In: Madden IV, ed. Neurobiology of Learning, Emotion and Affect. NY: Raven Press, Ltd., 1991: 307–347.Google Scholar
  5. 5.
    Collier HOJ. A general theory of the genesis of drug dependence by induction of receptors. Nature 1965; 205: 181–183.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang KJ, Eckel RW, Blanchard SG. Opioid peptides induced reduction of enkephalin receptors in cultured neuroblastoma cells. Nature 1982; 296: 446–448.PubMedCrossRefGoogle Scholar
  7. 7.
    Law PY, Hom DS, Loh HH. Downregulation of opiate receptor in neuroblastoma x glioma NG 10815 hybrid cells. J Biol Chem 1984; 259: 4096–4104.PubMedGoogle Scholar
  8. 8.
    Puttfarcken PS, Cox BM. Morphine-induced desensitization and downregulation at mu-receptor in 7315C pituitary tumor cells. Life Sci 1989; 45: 1937–1942.PubMedCrossRefGoogle Scholar
  9. 9.
    Zadina JE, Kastin AJ, Kersh D et al. TYR-MIF and hemorphin can act as opiate agonist as well as antagonist in the guinea pig ileum. Life Sci 1992; 51: 869–885.PubMedCrossRefGoogle Scholar
  10. 10.
    Morris BJ, Herz A. Control of opiate receptor number in vivo: Simultaneous kappa-receptor downregulation and mu-receptor upregulation following chronic agonist/antagonist treatment. Neuroscience 1989; 29: 433–442.PubMedCrossRefGoogle Scholar
  11. 11.
    Rothman RB. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 1992; 12: 129–138.PubMedCrossRefGoogle Scholar
  12. 12.
    Werling LL, McMahon PN, Cox BM. Selective changes in muopioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA 1989; 86: 6393–6397.PubMedCrossRefGoogle Scholar
  13. 13.
    Yoburn BC, Duttaroy A, Billings B. Dose-dependent down-regulation of opioid receptors in mice. Keystone, Colorado: Abstracts, INRC, 1992.Google Scholar
  14. 14.
    Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci 1992; 12: 2439–2450.PubMedGoogle Scholar
  15. 15.
    Terwilliger RZ, Beitner-Johnson D, Sevatino KA et al. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 1991; 548: 100–110.PubMedCrossRefGoogle Scholar
  16. 16.
    Bronstein DM, Przewlocki R, Akil H. Effects of morphine treatment on pro-opio-melanocortin systems in rat brain. Brain Res 1990; 519: 102–111.PubMedCrossRefGoogle Scholar
  17. 17.
    Hammonds RG, Nicholas P, Li CH. Beta-endorphin (1–27) is an antagonist of beta-endorphin analgesia. Proc Natl Acad Sci USA 1984; 81: 1389–1393.PubMedCrossRefGoogle Scholar
  18. 18.
    Nicolas P, Hammonds RG, Li CH. Beta-endorphin analgesia is inhibited by synthetic analogs of beta-endorphin. Proc Natl Acad Sci USA 1984; 81: 3074–3077.PubMedCrossRefGoogle Scholar
  19. 19.
    Schulteis G, Markou A, Gold L et al. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: A quantitative dose-response analysis. J Pharmacol Exp Ther 1994; 271: 1391–1398.PubMedGoogle Scholar
  20. 20.
    Wei EL, Loh HH, Way EL. Quantitative aspects of abstinence in morphine-dependent rats. J Pharmacol Exp Ther 1973; 184: 398–403.PubMedGoogle Scholar
  21. 21.
    Faris PK, Komisaruk BR, Watkins LR et al. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983; 219: 310–312.PubMedCrossRefGoogle Scholar
  22. 22.
    Galina ZH, Kastin AJ. Existence of antiopiate systems as illustrated by MIF-1/Tyr-MIF-1. Life Sci 1986; 39: 2153–2159.PubMedCrossRefGoogle Scholar
  23. 23.
    Yang HYT, Fratta W, Majane EA et al. Isolation sequencing, synthesis and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA 1985; 82: 7757–7761.PubMedCrossRefGoogle Scholar
  24. 24.
    Rehfeld JL. Neuronal cholecystokinin. One or two multiple transmitters. J Neurochem 1985; 44: 1–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Gibbs J, Young RC, Smith GP. Cholecystokinin elicits satiety in rats with open gatric fistulas. Nature 1973; 245: 323–325.PubMedCrossRefGoogle Scholar
  26. 26.
    Daugé V, Steimes P, Derrien M et al. CCK-8 effects on motivational and emotional states of rats involve CCK-A receptors of the posteromedial part of the nucleus accumbens. Pharmacol Biochem Behav 1989; 34: 157–163.PubMedCrossRefGoogle Scholar
  27. 27.
    Innis RB, Snyder SH. Cholecystokinin receptor binding in brain and pancreas. Regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. Eur J Pharmacol 1980; 65: 123–124.PubMedCrossRefGoogle Scholar
  28. 28.
    Moran TH, Robinson PH, Goldrich MS et al. Two brain cholecystokinin receptors: Implication for behavioral actions. Brain Res 1986; 362: 175–179.PubMedCrossRefGoogle Scholar
  29. 29.
    Durieux C, Ruiz-Gayo M, Roques BP. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCK-B agonist [3H]pBC 264. Eur J Pharmacol 1991; 209: 185–193.PubMedCrossRefGoogle Scholar
  30. 30.
    Kopin AS, Lee YM, McBride EW et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992; 89: 3605–3609.PubMedCrossRefGoogle Scholar
  31. 31.
    Wank SA, Harkins R, Jensen RT et al. Purification, molecular cloning and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 1992; 89: 3125–3129.PubMedCrossRefGoogle Scholar
  32. 32.
    Lee YM, Beinborn M, McBride EW et al. The human brain cholecystokinin-B/gastrin receptor. J Biol Chem 1993; 268: 8164–8169.PubMedGoogle Scholar
  33. 33.
    Hill DR, Woodruff GN. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res 1990; 526: 276–283.PubMedCrossRefGoogle Scholar
  34. 34.
    Faris PK. Opiate antagonist function of cholecystokinin in analgesia and energy balance systems. Ann NY Acad Sci 1985; 448: 437–447.PubMedCrossRefGoogle Scholar
  35. 35.
    Zetler G. Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8). Neuropharmacology 1980; 19: 415–422.PubMedCrossRefGoogle Scholar
  36. 36.
    Baber NS, Dourish CT, Hill DR. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1989; 39: 307–328.PubMedCrossRefGoogle Scholar
  37. 37.
    Dourish CT, O’Neill MF, Couglan J et al. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990; 176: 35–44.PubMedCrossRefGoogle Scholar
  38. 38.
    Dourish CT, O’Neill MF, Schaeffer LW et al. The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey. J Pharmacol Exp Ther 1990; 255: 1158–1165.PubMedGoogle Scholar
  39. 39.
    Lavigne GJ, Millington WR, Mueller GP. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 1992; 21: 119–129.PubMedCrossRefGoogle Scholar
  40. 40.
    Zhou Y, Sun YH, Zhang ZW et al. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCJB receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol 1993; 234: 147–154.PubMedCrossRefGoogle Scholar
  41. 41.
    Maldonado R, Derrien M, Noble F et al. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. NeuroReport 1993; 7: 947–950.CrossRefGoogle Scholar
  42. 42.
    Valverde O, Maldonado R, Fournié-Zaluski MC et al. CCK-B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 1994; 270: 77–88.PubMedGoogle Scholar
  43. 43.
    Valverde O, Blommaert A, Turcaud S et al. The CCK-B antagonist PD-134,308 induces a long-lasting potentiation of antinociceptive responses mediated by endogenous enkaphalins in the rat tail-flick test. Eur J Pharmacol 1995; 286: 79–93.PubMedCrossRefGoogle Scholar
  44. 44.
    Rattray M, Jordan CC, De Belleroche J. The novel CCK antagonist L-364,718 abolished caerulein-but potentiated morphine-induced antinociception. Eur J Pharmacol 1988; 152: 163–166.PubMedCrossRefGoogle Scholar
  45. 45.
    O’Neill MF, Dourish CT, Iversen SD. Morphine analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology 1989; 28: 243–248.PubMedCrossRefGoogle Scholar
  46. 46.
    Suh HH, Tseng LF. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice. Eur J Pharmacol 1990; 179: 329–339.PubMedCrossRefGoogle Scholar
  47. 47.
    Wiesenfeld-Hallin Z, Xu XJ, Hughes J et al. PD-134,308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA 1990; 87: 7105–7109.PubMedCrossRefGoogle Scholar
  48. 48.
    Kellstein DE, Price DD, Mayer DE. Cholecystokinin and its antagonist lorgumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons. Brain Res 1991; 540: 302–306.PubMedCrossRefGoogle Scholar
  49. 49.
    Sullivan AF, Hewett K, Dickenson AH. Differential modulation of alpha 2-adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in the rat dorsal horn: An electrophysiological study. Brain Res 1994; 662: 141–147.PubMedCrossRefGoogle Scholar
  50. 50.
    Stengaard-Pedersen K, Larson LI. Localization and opiate receptor binding of enkephalin, CCK and ACTH/beta-endorphin in the rat central nervous system. Peptides 1981; 2: 3–19.Google Scholar
  51. 51.
    Xu XJ, Puke MJC, Verge VMK et al. Upregulation of cholecystokinin in primary sensory neurons is associated with morphine in-sensitivity in experimental neuropathic pain in rat. Neurosci Lett 1993; 152: 129–132.PubMedCrossRefGoogle Scholar
  52. 52.
    Kapas L, Benedek G, Penek B. Cholecystokinin interferes with the thermoregulatory effects of exogenous and endogenous opioids. Neuropeptides 1989; 14: 85–92.PubMedCrossRefGoogle Scholar
  53. 53.
    Ben-Horin N, Ben-Horin E, Frenk H. The effects of proglumide on morphine-induced mortility changes. Psychopharmacology 1984; 84: 541–543.PubMedCrossRefGoogle Scholar
  54. 54.
    Schnur P, Raigoza VP, Sanchez MR et al. Cholecystokinin antagonizes morphine-induced hypoactivity and hyperactivity in hamsters. Pharmacol Biochem Behav 1986; 25: 1067–1070.PubMedCrossRefGoogle Scholar
  55. 55.
    Schnur P, Cesar SS, Foderaro MA et al. Efffects of cholecystokinin on morphine-elicited hyperactivity in hamsters. Pharmacol Biochem Behav 1991; 39: 581–586.PubMedCrossRefGoogle Scholar
  56. 56.
    Miller KK, Lupica CR. Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CAI region of the rat hippocampal slice. J Pharmacol Exp Ther 1994; 268: 753–761.PubMedGoogle Scholar
  57. 57.
    Itoh S, Katsuura G. Effects of beta-endorphin, thyrotropin-releasing hormone and cholecystokinin on body-shaking behavior in rats. Jpn J Physiol 1982; 32: 667–675.PubMedCrossRefGoogle Scholar
  58. 58.
    Higgins GA, Nguyen P, Sellers EM. Morphine place conditioning is differentially affected by CCK-A and CCK-B receptor antagonists. Brain Res 1992; 572: 208–215.PubMedCrossRefGoogle Scholar
  59. 59.
    Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety. TIPS 1993; 14: 244–249.Google Scholar
  60. 60.
    Smadja C, Maldonado R, Turcaud S et al. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalins’ antidepressant-like effects. Psychopharmacology 1995; 120: 400–408.PubMedCrossRefGoogle Scholar
  61. 61.
    Noble F, Smadja C, Roques BP. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta opioid agonists. J Pharmacol Exp Ther 1994; 271: 1127–1134.PubMedGoogle Scholar
  62. 62.
    Faris PK, Beinfeld MC, Scallet AC et al. Increase in hypothalamic cholecystokinin following acute and chronic morphine. Brain Res 1986; 367: 405–407.PubMedCrossRefGoogle Scholar
  63. 63.
    Benoleil JJ, Bourgoin S, Mauborgne A et al. Differential inhibitory/stimulatory modulation of spinal CCK release by mu-opioid and delta-opioid agonists, and selective blockade of mu-dependent inhibition by k receptor stimulation. Neurosci Lett 1991; 124: 204–207.CrossRefGoogle Scholar
  64. 64.
    Benoleil JJ, Mauborgne A, Bourgoin S et al. Opioid control of the in vivo release of CCK-like material from the rat substantia nigra. J Neurochem 1992; 58: 916–920.CrossRefGoogle Scholar
  65. 65.
    Rattray M, De Belleroche J. Morphine action on cholecystokinin octapeptide release from rat periaqueductal gray slices: Sensitization by naloxone. Neuropeptides 1987; 10: 189–200.Google Scholar
  66. 66.
    Rodriguez RE, Sacristan MP. In vivo release of CCK-8 from the dorsal horn of the rat: Inhibition by DAGOL. FEBS Lett 1989; 250: 215–217.Google Scholar
  67. 67.
    Ruiz-Gayo M, Durieux C, Fournié-Zaluski MC et al. Stimulation of delta opioid receptors reduces the in vivo binding of the CCK-Bselective agonist [3H]pBC 264: Evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 1992; 59: 1805–1811.PubMedCrossRefGoogle Scholar
  68. 68.
    Gall C, Lauterborn J, Burks D et al. Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res 1987; 403: 403–408.PubMedCrossRefGoogle Scholar
  69. 69.
    Pohl M, Benoliel JJ, Bourgoin S et al. Regional distribution of calcitonin gene-related peptide-, substance P-, cholecystokinin-, Met5-enkephalin-, and dynorphin A (1–8)-like materials in the spinal cord and dorsal root ganglia of adult rats: Effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 1990; 55: 1122–1130.PubMedCrossRefGoogle Scholar
  70. 70.
    Tang J, Chou J, Iadarola M et al. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 1984; 23: 715–718.PubMedCrossRefGoogle Scholar
  71. 71.
    Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of morphine analgesia and apparent reversal of morphine tolerance by proglumide. Science 1984; 224: 395–396.PubMedCrossRefGoogle Scholar
  72. 72.
    Panerai AE, Rovati LC, Cocco E et al. Dissociation of tolerance and dependence to morphine: A possible role for cholecystokinin. Brain Res 1987; 410: 52–60.PubMedCrossRefGoogle Scholar
  73. 73.
    Dourish CT, Hawley D, Iversen SD. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur J Pharmacol 1988; 147: 469–472.PubMedCrossRefGoogle Scholar
  74. 74.
    Ding XZ, Fan SG, Han JS. Reversal of tolerance to morphine but no potentiation of morphine-induced analgesia by antiserum against cholecystokinin octapeptide. Neuropharmacology 1986; 25: 1155–1160.PubMedCrossRefGoogle Scholar
  75. 75.
    Xu XJ, Wiesenfeld-Hallin Z, Hughes J et al. CI988, a selective antagonist of cholecystokinin-B receptors, prevents morphine tolerance in rats. Br J Pharmacol 1992; 105: 591–596.PubMedCrossRefGoogle Scholar
  76. 76.
    Ding XZ, Bayer BM. Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res 1993; 625: 139–144.PubMedCrossRefGoogle Scholar
  77. 77.
    Pu S, Zhuang H, Lu Z et al. Cholecystokinin gene expression in rat amygdaloid neurons: Normal distribution and effect of morphine tolerance. Mol Brain Res 1994; 21: 183–189.PubMedCrossRefGoogle Scholar
  78. 78.
    Maldonado R, Valverde O, Ducos B et al. Inhibition of morphine withdrawal syndrome by the association of a peptidase inhibitor and a CCK-B antagonist. Br J Pharmacol 1995; 114: 1031–1039.PubMedCrossRefGoogle Scholar
  79. 79.
    Hughes J, Boden P, Costall B et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87: 6728–6732.PubMedCrossRefGoogle Scholar
  80. 80.
    Pournaghash S, Riley A. Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats. Pharmacol Biochem Behav 1991; 38: 479–484.PubMedCrossRefGoogle Scholar
  81. 81.
    Maldonado R, Valverde O, Derrien M et al. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacol Biochem Behav 1994; 48: 363–369.PubMedCrossRefGoogle Scholar
  82. 82.
    Charpentier B, Durieux C, Pélaprat D et al. Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides 1988; 9: 835–841.PubMedCrossRefGoogle Scholar
  83. 83.
    Derrien M, Noble F, Maldonado R et al. CCK-A or CCK-B receptor activation leads to antinociception or to hyperalgesia, respectively: Evidence for an indirect interaction with the opioidergic system. Neurosci Lett 1993; 160: 193–196.PubMedCrossRefGoogle Scholar
  84. 84.
    Koob GF, Maldonado R, Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 1992; 15: 186–191.PubMedCrossRefGoogle Scholar
  85. 85.
    Ravard S, Dourish T. Cholecystokinin and anxiety. Trends Pharmacol Sci 1990; 11: 271–273.PubMedCrossRefGoogle Scholar
  86. 86.
    Costall B, Domeney AM, Hughes J et al. Anxiolytic effects of CCK-B antagonists. Neuropeptides 1991; 19 (Suppl): 65–73.PubMedCrossRefGoogle Scholar
  87. 87.
    Dockray GJ, Vaillant C, Williams RG. New vertebrate brain-gut peptide related to a molluscan neuropeptide and an opioid peptide. Nature 1981; 293: 656–657.PubMedCrossRefGoogle Scholar
  88. 88.
    Weber E, Evans CJ, Samuelsson SJ et al. Novel peptide neuronal system in rat brain and pituitary. Science 1981; 214: 1248–1251.PubMedCrossRefGoogle Scholar
  89. 89.
    Allard M, Theodosis DT, Rousselot P et al. Characterization and localization of a putative morphine-modulating peptide, FLFQPQRFamide, in the rat spinal cord: Biochemical and immunocytochemical studies. Neuroscience 1991; 40: 81–92.PubMedCrossRefGoogle Scholar
  90. 90.
    Kivipelto L, Majane EA, Yang HY et al. Immunohistochemical distribution and partial characterization of FLFQPQRFamide-like peptides in the central nervous system. J Comp Neurol 1989; 286: 269–287.PubMedCrossRefGoogle Scholar
  91. 91.
    Kivipelto L, Panula P. Origin and distribution of neuropeptideFF-like immunoreactivity in the spinal cord of rats. J Comp Neurol 1991; 307: 107–119.PubMedCrossRefGoogle Scholar
  92. 92.
    Majane EA, Panula P, Yang HY. Rat brain regional distribution and spinal cord neuronal pathway of FLFQPQRF-NH2, a mammalian FMRF-NH2-like peptide. Brain Res 1989; 494: 1–12.PubMedCrossRefGoogle Scholar
  93. 93.
    Allard M, Geoffre S, Legendre P et al. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: A binding study. Brain Res 1989; 500: 169–176.PubMedCrossRefGoogle Scholar
  94. 94.
    Allard M, Zajac JM, Simonnet G. Autoradiographic distribution of receptors to FLFQPQRFamide, a morphine-modulating peptide, in the rat central nervous system. Neuroscience 1992; 49: 101–116.PubMedCrossRefGoogle Scholar
  95. 95.
    Kavaliers M, Hirst M. FMRFamide, a putative endogenous opiate antagonist: Evidence from suppression of defeat-induced analgesia and feeding in mice. Neuropeptides 1985; 6: 485–494.PubMedCrossRefGoogle Scholar
  96. 96.
    Kavaliers M, Hirst M. Inhibitory influences of and on stress-induced opioid analgesia and activity. Brain Res 1986; 372: 370–374.PubMedCrossRefGoogle Scholar
  97. 97.
    Kavaliers M. Inhibitory influences of mammalian FMRFamide (PheMet-Arg-Phe-amide)-related peptides on nociception and morphine-and stress-induced analgesia in mice. Neurosci Lett 1990; 115: 307–312.PubMedCrossRefGoogle Scholar
  98. 98.
    Oberling P, Stinus L, Le Moal M et al. Biphasic effect on nociception and antiopiate activity of the neuropeptide FF (FLFQPQRFamide) in the rat. Peptides 1993; 14: 919–924.PubMedCrossRefGoogle Scholar
  99. 99.
    Kavaliers M, Hirst M, Mathers A. Inhibitory influences of FMRF amide on morphine-and deprivation-induced feeding. Neuroendocrinology 1985; 40: 533–535.PubMedCrossRefGoogle Scholar
  100. 100.
    Kavaliers M, Yang HYT. IgG from antiserum against endogenous mammalian FMRF-NH2-related peptides augments morphine-and stress-induced analgesia in mice. Peptides 1989; 10: 741–745.PubMedCrossRefGoogle Scholar
  101. 101.
    Lake JR, Hammond MV, Shaddox RC et al. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 1991; 132: 29–32.PubMedCrossRefGoogle Scholar
  102. 102.
    Lake JR, Hebert KM, Payza K et al. Analog of neuropeptide FF attenuates morphine tolerance. Neurosci Lett 1992; 146: 203–206.PubMedCrossRefGoogle Scholar
  103. 103.
    Tang J, Yang HY, Costa E. Inhibition of spontaneous and opiate-modified nociception by an endogenous neuropeptide with PheMet-Arg-Phe-NH2-like immunoreactivity. Proc Natl Acad Sci USA 1984; 81: 5002–5005.PubMedCrossRefGoogle Scholar
  104. 104.
    Rothman RB, Brady LS, Xu H et al. Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-GlnArgPhe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain. Peptides 1993; 14: 1271–1277.PubMedCrossRefGoogle Scholar
  105. 105.
    Magnuson DSK, Sullivan AF, Simonnet G et al. Differential interaction of cholecystokinin and FLFQPQRF-NH2 with mu and delta opioid antinociception in the rat spinal cord. Neuropeptides 1990; 16: 213–218.PubMedCrossRefGoogle Scholar
  106. 106.
    Malin DH, Lake JR, Fowler DE et al. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 1990; 11: 277–280.PubMedCrossRefGoogle Scholar
  107. 107.
    Malin DH, Lake JR, Hammond MV et al. FMRF-NH2-like mammalian octapeptide: Possible role in opiate dependence and abstinence. Peptides 1990; 11: 969–972.PubMedCrossRefGoogle Scholar
  108. 108.
    Malin DH, Lake JR, Leyva JE et al. Analog of neuropeptide FF attenuates morphine abstinence syndrome. Peptides 1991; 12: 1011–1014.PubMedCrossRefGoogle Scholar
  109. 109.
    Stinus L, Allard M, Gold L et al. Changes in CNS neuropeptide FF-like material, pain sensitivity, and opiate dependence following chronic morphine treatment. Peptides 1995; 16: 1235–1241.PubMedCrossRefGoogle Scholar
  110. 110.
    Trujillo KE, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85–87.PubMedCrossRefGoogle Scholar
  111. 111.
    Devillers JP, Simonnet G. Modulation of neuropeptide FF release from rat spinal cord slices by glutamate. Involvement of NMDA receptors. Eur J Pharmacol 1994; 271: 185–192.PubMedCrossRefGoogle Scholar
  112. 112.
    Hoffman O, Wiesenfeld-Hallin Z. The CCK-B receptor antagonist CI988 reverses tolerance to morphine in rats. NeuroReport 1994; 5: 2565–2568.CrossRefGoogle Scholar
  113. 113.
    Corbett AD, Paterson SJ, McKnight AT et al. Dynorphin are ligands for the kappa-subtype of opiate receptor. Nature 1982; 299: 79–81.PubMedCrossRefGoogle Scholar
  114. 114.
    Friedman HJ, Jen MF, Chang JK et al. Dynorphin: A possible modulatory peptide on morphine or beta-endorphin analgesia in mice. Eur J Pharmacol 1981; 69: 357–360.PubMedCrossRefGoogle Scholar
  115. 115.
    Fujimoto J, Arts KS. Clonidine, administered intracerebroventricularly in mice, produces an antianalgesic effect which may be mediated spinally by dynorphin A(1–17). Neuropharmacology 1990; 29: 351–358.PubMedCrossRefGoogle Scholar
  116. 116.
    Fujimoto J, Arts KS, Rady J et al. Spinal dynorphin A(1–17): Possible mediator of antianalgesic action. Neuropharmacology 1990; 29: 609–617.PubMedCrossRefGoogle Scholar
  117. 117.
    Fujimoto J, Arts KS, Rady J et al. Intracerebroventricular analgesia enhanced by intrathecal dynorphin A(1–17) antibody. Prog Clin Biol 1990; 328: 433–436.Google Scholar
  118. 118.
    Fujimoto J, Holmes B. Systemic single-dose morphine pretreatment desensitizes mice to the spinal antianalgesic action of dynorphin A(1–17). J Pharmacol Exp Ther 1990; 254: 1–7.PubMedGoogle Scholar
  119. 119.
    Jones DNC, Holtzman SG. Long-term kappa-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol 1992; 215: 345–348.PubMedCrossRefGoogle Scholar
  120. 120.
    Spanagel R, Almeida OFX, Bard C et al. Endogenous kappa-opioid systems in opiate withdrawal: Role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology 1994; 115: 121–127.PubMedCrossRefGoogle Scholar
  121. 121.
    Maldonado R, Negus S, Koob GF. Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta-and kappa-selective opioid antagonists. Neuropharmacology 1992; 31: 1231–1241.PubMedCrossRefGoogle Scholar
  122. 122.
    Suzuki T, Narita M, Takahahi Y et al. Effects of nor-binaltorphimine on the development of analgesic tolerance to and physical dependence on morphine. Eur J Pharmacol 1992; 213: 91–97.PubMedCrossRefGoogle Scholar
  123. 123.
    Wei E, Loh HH, Way EL. Brain sites of precipitated abstinence in morphine-dependent rats. J Pharmacol Exp Ther 1973; 185: 108–115.PubMedGoogle Scholar
  124. 124.
    Calvino B, Lagowska J, Ben-Ari Y. Morphine withdrawal syndrome: Differential participation of structures located within the amygdaloid complex and striatum of the rat. Brain Res 1979; 177: 19–34.PubMedCrossRefGoogle Scholar
  125. 125.
    Routtenberg A, Sladek J, Bondareff W. Historical fluorescence after application of neurochemicals to caudate nucleus and septal area in vivo. Science 1968; 161: 272–274.PubMedCrossRefGoogle Scholar
  126. 126.
    Bondareff W, Routtenberg A, Narotzky R et al. Intrastriatal spreading of biogenic amines. Exp Neurol 1970; 28: 213–229.PubMedCrossRefGoogle Scholar
  127. 127.
    Schroeder RL, Weinger MB, Vakassian L et al. Methylnaloxonium diffuses out of the brain more slowly than naloxone after direct intracerebral injection. Neurosci Lett 1991; 121: 173–177.PubMedCrossRefGoogle Scholar
  128. 128.
    Bozarth MA, Wise RA. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 1984; 224: 516–517.PubMedCrossRefGoogle Scholar
  129. 129.
    Maldonado R, Stinus L, Gold LH et al. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 1992; 261: 669–677.PubMedGoogle Scholar
  130. 130.
    Koob GF, Wall TL, Bloom FE. Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology (Berlin) 1989; 98: 530–534.CrossRefGoogle Scholar
  131. 131.
    Stinus L, Le Moal M, Koob GE The nucleus accumbens and amygdala as possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 1990; 37: 767–773.PubMedCrossRefGoogle Scholar
  132. 132.
    Maldonado R, Koob GF. Modification in the development of morphine dependence in rats by electrolytic lesion of the locus coeruleus. Brain Res 1993; 605: 128–138.PubMedCrossRefGoogle Scholar
  133. 133.
    Dahlstrom A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1965; 232 (Suppl): 1–55.Google Scholar
  134. 134.
    Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: New evidence of anatomical and physiological specificity. Physiol Rev 1983; 63: 844–914.PubMedGoogle Scholar
  135. 135.
    Moore RY, Bloom FE. Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems. Annu Rev Neurosci 1979; 2: 113–168.PubMedCrossRefGoogle Scholar
  136. 136.
    Aghajanian GG, Wang YY. Common alpha-2 and opiate effector mechanisms in the locus coeruleus intracellular studies in brain slices. Neuropharmacology 1987; 26: 793–799.PubMedCrossRefGoogle Scholar
  137. 137.
    Redmond DE, Jr., Huang YH, Snyder DR et al. Behavioral effects of stimulation of the nucleus locus coeruleus in the stump-tailed monkey (Maccaca arctoides). Brain Res 1976; 116: 502–510.PubMedCrossRefGoogle Scholar
  138. 138.
    Redmond DE Jr, Huang YH. Current concepts II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci 1979; 25: 2149–2162.PubMedCrossRefGoogle Scholar
  139. 139.
    Redmond DE Jr, Huang YH. The primate locus coeruleus and effects of clonidine on opiate withdrawal. J Clin Psychiatry 1982; 46: 25–29.Google Scholar
  140. 140.
    Grant SJ, Huang YH, Redmond E Jr. Behavior of monkeys during opiate withdrawal and locus coeruleus stimulation. Pharmacol Biochem Behav 1988; 30: 13–19.PubMedCrossRefGoogle Scholar
  141. 141.
    Bird SJ, Kuhar MJ. Iontophoretic application of opiates to the locus coeruleus. Brain Res 1977; 122: 523–533.PubMedCrossRefGoogle Scholar
  142. 142.
    Andrade R, Vandermaelen CP, Aghajanian GK. Morphine tolerance and dependence in the locus coeruleus: Single-cell studies in brain slices. Eur J Pharmacol 1983; 91: 161–169.PubMedCrossRefGoogle Scholar
  143. 143.
    Aghajanian GK. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature 1978; 276: 186–188.PubMedCrossRefGoogle Scholar
  144. 144.
    Llorens C, Martres M, Bardry M et al. Hypersensitivity to noradrenaline in cortex after chronic morphine: Relevance to tolerance and dependence. Nature 1978; 274: 603–605.PubMedCrossRefGoogle Scholar
  145. 145.
    Laverty R, Roth RH. Clonidine reverses the increased norepinephrine turnover during morphine withdrawal in rats. Brain Res 1980; 182: 482–485.PubMedCrossRefGoogle Scholar
  146. 146.
    Crawley JN, Laverty R, Roth RH. Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal. Eur J Pharmacol 1979; 57: 247–250.PubMedCrossRefGoogle Scholar
  147. 147.
    DiStefano PS, Brown OM. Biochemical correlates of morphine withdrawal. 2. Effects of clonidine. J Pharmacol Exp Ther 1985; 233: 339–344.PubMedGoogle Scholar
  148. 148.
    Nestler EJ, Tallman JF. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol 1988; 33: 127–132.PubMedGoogle Scholar
  149. 149.
    Rasmussen K, Beitner-Johnson DB, Krystal JH et al. Opiate withdrawal and rat locus coeruleus: Behavioral, electrophysiological, and biochemical correlates. J Neurosci 1990; 10: 2308–2317.PubMedGoogle Scholar
  150. 150.
    Esposito E, Kruszewska A, Ossowska G et al. Noradrenergic and behavioral effects of naloxone injected into the locus coeruleus of morphine-dependent rats and their control by clonidine. Psychopharmacology 1987; 93: 393–396.PubMedCrossRefGoogle Scholar
  151. 151.
    Glick SD, Charap AD. Morphine dependence in rats with medial forebrain bundle lesions. Psychopharmacologia (Berlin) 1973; 34: 343–348.Google Scholar
  152. 152.
    Britton KT, Svensson T, Schwartz J et al. Dorsal noradrenergic bundle lesions fail to alter opiate withdrawal or suppression of opiate withdrawal by clonidine. Life Sci 1984; 34: 133–139.PubMedCrossRefGoogle Scholar
  153. 153.
    Franz DN, Hare BD, McCloskey KL. Spinal sympathetic neurons: Possible sites of opiate withdrawal suppression by clonidine. Science 1982; 215: 1643–1645.PubMedCrossRefGoogle Scholar
  154. 154.
    Delander,GE, Takemori AE. Spinal antagonism of tolerance and dependence induced by systemically administered morphine. Eur J Pharmacol 1983; 94: 35–42.CrossRefGoogle Scholar
  155. 155.
    Turner RM, Marshall DC, Buccafusco JJ. Supraspinal and spinal components of naloxone-induced morphine withdrawal. Pharmacologist 1984; 26: 197.Google Scholar
  156. 156.
    Buccafusco JJ, Marshall DC. Dorsal root lesions block the expression of morphine withdrawal elicited from the rat spinal cord. Neurosci Lett 1985; 59: 319–324.PubMedCrossRefGoogle Scholar
  157. 157.
    Friedler G, Bhargava HN, Quock R et al. The effect of 6hydroxydopamine on morphine tolerance and physical dependence. J Pharmacol Exp Ther 1972; 183: 49–55.PubMedGoogle Scholar
  158. 158.
    Elchisak MA, Rosecrans JA. Development of morphine tolerance and physical dependence in rats depleted of brain catecholamines by 6-hydroxydopamine. Neuropharmacology 1979; 18: 175–182.PubMedCrossRefGoogle Scholar
  159. 159.
    Funada M, Suzuki T, Sugano Y et al. Role of the ß-adrenoceptors in the expression of morphine withdrawal signs. Life Sci 1994; 54: 113–118.CrossRefGoogle Scholar
  160. 160.
    Bozarth MA. Physical dependence produced by central morphine infusions: An anatomical mapping study. Neurosci Biobehav Rev 1994; 18: 373–383.CrossRefGoogle Scholar
  161. 161.
    Matsuoka I, Maldonado R, Defer N et al. Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA. Eur J Pharmacol Mol Sect 1994; 268: 215–221.CrossRefGoogle Scholar
  162. 162.
    Maldonado R, Valverde O, Garbay C et al. Protein kinases mediate the expression of opiate withdrawal in the locus coeruleus and periayueductal gray matter. Naunyn Schtniedebergs Arch Pharmacol 1995; 352: 565–575.Google Scholar
  163. 163.
    Maldonado R, Feger J, Fournié-Zaluski MC et al. Differences in physical dependence induced by selective mu or delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Brain Res 1990; 520: 247–254.PubMedCrossRefGoogle Scholar
  164. 164.
    Noble F, Coric P, Fournié-Zaluski MC et al. Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes RB 101. Eur J Pharmacol 1992; 223: 91–96.PubMedCrossRefGoogle Scholar
  165. 165.
    Williams JT, Christie MJ, North RA et al. Potentiation of enkephalin action by peptidase inhibitors in rat locus coeruleus in vitro. J Pharmacol Exp Ther 1987; 243: 397–401.PubMedGoogle Scholar
  166. 166.
    Christie MJ, Williams JT, North RA. Cellular mechanisms of opioid tolerance: Studies in single brain neurons. J Pharmacol Exp Ther 1987; 32: 633–638.Google Scholar
  167. 167.
    Rasmussen K, Aghajanian GK. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: Attenuation by lesion of the nucleus paragigantocellularis. Brain Res 1989; 505: 346–350.PubMedCrossRefGoogle Scholar
  168. 168.
    Tung CS, Grenhoff J, Svensson TH. Morphine withdrawal responses of rat locus coeruleus neurons are blocked by an excitatory amino acid antagonist. Acta Physiol Scand 1990; 138: 581–582.PubMedCrossRefGoogle Scholar
  169. 169.
    Rasmussen K, Krystal JH, Aghajanian GK. Excitatory amino acids and morphine withdrawal: Differential effects of central and peripheral kynurenic acid administration. Psychopharmacology 1991; 105: 508–512.PubMedCrossRefGoogle Scholar
  170. 170.
    Akaoka A, Aston-Jones G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J Neurosci 1991; 11: 3830–3839.PubMedGoogle Scholar
  171. 171.
    Hong M, Milne B, Jhamandas K. Evidence for the involvement of excitatory amino acid pathways in the development of precipitated withdrawal from acute and chronic morphine: An in vivo voltammetric study in the rat locus coeruleus. Brain Res 1994; 623: 131–141.CrossRefGoogle Scholar
  172. 172.
    Aghajanian GK, Kogan JH, Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: An in vivo microdialysis study. Brain Res 1994; 636: 126–130.PubMedCrossRefGoogle Scholar
  173. 173.
    Zhang T, Feng Y, Rockhold RW et al. Naloxone-precipitated morphine withdrawal increases pontine glutamate levels in the rat. Life Sci 1994; 55: PL25–31.PubMedCrossRefGoogle Scholar
  174. 174.
    Kogan JH, Nestler EJ, Aghajanian GK. Elevated basal firing rates and enhanced responses to 8-Br-cAMP in locus coeruleus nerons in brain slices from opiate-dependent rats. Eur J Pharmacol 1992; 211: 47–53.PubMedCrossRefGoogle Scholar
  175. 175.
    Hayward MD, Duman RS, Nestler EJ. Induction of the c-fos proto-oncogene during opiate withdrawal in the locusGoogle Scholar
  176. 176.
    Stornetta RL, Norton FE, Guyenet PG. Autonomic areas of ratbrain exhibit increased Fos-like immunoreactivity duringopiate withdrawal in rats. Brain Res 1993; 624: 19–28.PubMedCrossRefGoogle Scholar
  177. 177.
    Ronken E, Mulder AH, Schoffelmer ANM. Chronic activation of mu- and kappa-opioid receptors in cultured catecholaminergic nue-rons from rat brain causes neuronal supersentivicy without receptor densensitization. J Pharmacol Exp Ther 199; 268: 595–599.Google Scholar
  178. 178.
    Ronken E, Mulder AH, Schoffelmeer ANM. Chronic activation of mu- and kappa-opioid receptors in cultured catecholaminergic neu¬rons from rat brain causes neuronal supersentivity without receptor densensitization. J Pharmacol Exp Ther 1994; 268: 595–599.PubMedGoogle Scholar
  179. 179.
    Laschka E, Teschemcher P, Mehrain P et al. Sites of action of morphine involved in the development of physical dependence in rats. II. Morpline withdrawal precipitated by applicaytion of mor-phine antagonists into resticted parts of the ventricular system and by mictionjecyion into various brain areas. Psychpoarmacoloaia 1976; 46: 141–1477.CrossRefGoogle Scholar
  180. 180.
    Herz A, Teschemacher HJ, Albus K et al. Morphine abstinence syndrome in rabbits precipitated by injection of orphine antagonists into the ventricular system and restricted parts of it. Psychopharmacologia 1972; 26: 219–236.Google Scholar
  181. 181.
    Dourish CT, O’Neill MF, Schaeffer LW But not morphine-induced respiratory depression in the squirrel monkey. J Pharmacol Exp Ther 1990; 255: 1158–1165.PubMedGoogle Scholar
  182. 182.
    Laschka E, Teschemacher P, Mehrain P et al. Sites of action of electrophysiological, and biochemical correlates. J Neurosci Brain Res 1990; 525: 256–266.CrossRefGoogle Scholar
  183. 183.
    Araki H, Uchiyama-Tsutuli Y, Aihara H et al. Effects of chronic administration of haloperidol, methamphetamine or cocaine on “wet dog shakes” elicited by stimulation of the rat hippocampus. Arch Int Pharmacodyn Ther 1989; 297: 217–224.PubMedGoogle Scholar
  184. 184.
    Wei E, Loh HH, Way EL. Neuroanatomical correlates of reduction of enkephalin receptors in cultured mor-phine dependence. Science 1972; 177: 616–159.PubMedCrossRefGoogle Scholar
  185. 185.
    Mitchell CL, Grimes LM, Hong JS. Granule cells in the ventral dentate gyrus are essential for kainic acid-induced wet dog shakes but not those induced by precipitated abstinence in morphine-dependent rats. Brain Res 1990; 511: 338–340.PubMedCrossRefGoogle Scholar
  186. 186.
    Maldonado R, Fournié-Zaluski MC, Roques BP. Attenuation of the morphine withdrawal syndrome by inhibition of the endog-enous enkephalin catabolism into the periaqueductal gray matter.Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 466–472.Google Scholar
  187. 187.
    Isaacson RL, Lanthorn TH. Hippocampal involvement in the pharmacological induction of withdrawal-like behaviors. Fed Proc 1981; 40: 1500–1512.Google Scholar
  188. 188.
    Miyamoto Y, Takemori AE. Sites of action of naloxone in precipitating withdrawal jumping in morphine-dependent mice: Investigations by the ED50 value and CNS content of naloxone. Drug Alcohol Depend 1993; 32: 163–167.PubMedCrossRefGoogle Scholar
  189. 189.
    Brent PJ, Chahl LA. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea pigs is not mediated by sigma binding sites. Eur J Neuropsychopharmacol 1993; 3: 23–32.CrossRefGoogle Scholar
  190. 190.
    Kerr FWL, Pozuelo J. Suppression of physical dependence and induction of hypersensitivity to morphine by sterotaxic hypothalamic lesions in addicted rats. A new theory of addiction. Mayo Clin Proc 1971; 46: 653–665.Google Scholar
  191. 191.
    Wilder A, Norrell H, Miller D. Limbic system and opioid addiction in the rat. Exp Neurol 1972; 34: 543–557.CrossRefGoogle Scholar
  192. 192.
    Le Gal la Salle G, Lagowska J. Amygdaloid kindling procedure reduces severity of morphine withdrawal syndrome in rats. Brain Res 1980; 184: 239–242.CrossRefGoogle Scholar
  193. 193.
    Tremblay EC, Charton G. Anatomical correlates of morphine withdrawal syndrome: Differential participation of structures located within the limbic system and striatum. Neurosci Lett 1981; 23: 137–142.PubMedCrossRefGoogle Scholar
  194. 194.
    Adler MW, Geller EB, Beeton PB et al. Inability of acute or chronic thalamic, limbic, or cortical lesions to alter narcotic dependence and abstinence in rats. Dev Neurosci 1978; 4: 51–52.Google Scholar
  195. 195.
    Wei E, Tseng LF, Loh HH et al. Similarity of morphine abstinence signs to thermoregulatory behaviour. Nature 1974; 247: 398–340.PubMedCrossRefGoogle Scholar
  196. 196.
    Kerr FWL. The role of the lateral hypothalamus in opiate dependence. In: Zimmermann E, George R, eds. Narcotics and the Hypothalmus. New York: Raven Press, 1974: 23–35.Google Scholar
  197. Lomax P, Ary M. Sites of action of narcotic analgesics in the hypothalamus. In: Zimmerman E, George R, eds. Narcotics and the Hypothalamus. New York: Raven Press, 1974: 37–47.Google Scholar
  198. 198.
    Baumeister AA, Anticich TG, Hebert G et al. Evidence that physical dependence on morphine is mediated by the ventral midbrain. Neuropharmacology 1989; 28: 1151–1157.PubMedCrossRefGoogle Scholar
  199. 199.
    Baumeister AA, Richard AL, Richmond-Landeche L et al. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome. Neuropharmacology 1992; 31: 835–841.PubMedCrossRefGoogle Scholar
  200. 200.
    Bläsig J, Papeschi R, Gramsch C et al. Central serotonergic mechanisms and development of morphine dependence. Drug Alcohol Depend 1976; 1: 221–232.PubMedCrossRefGoogle Scholar
  201. 201.
    Bederson JB, Fields HL, Barbaro NM. Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens Mot Res 1990; 7: 185–203.PubMedCrossRefGoogle Scholar
  202. 202.
    Yap C, Taylor D. Involvement of 5-HT2 receptors in the wet dog shake behavior induced by 5-hydroxytryptophan in the rat. Neuropharmacology 1983; 22: 801–804.PubMedCrossRefGoogle Scholar
  203. 203.
    Araki H, Uchiyama-Tsutuli Y, Aihara H et al. Effects of chronic administration of haloperidol, methamphetamine or cocaine on “wet dog shakes” elicited by stimulation of the rat hippocampus. Arch Int Pharmacodyn Ther 1989; 297: 217–224.PubMedGoogle Scholar
  204. 204.
    Mitchell CL, Grimes LM, Hong JS. Granule cells in the ventral dentate gyrus are essential for kainic acid-induced wet dog shakes but not those induced by precipitated abstinence in morphine-dependent rats. Brain Res 1990; 511: 338–340.PubMedCrossRefGoogle Scholar
  205. 205.
    Isaacson RL, Lanthorn TH. Hippocampal involvement in the pharmacological induction of withdrawal-like behaviors. Fed Proc 1981; 40: 1500–1512.Google Scholar
  206. 206.
    Buccafusco JJ. Cardiovascular changes during morphine withdrawal in the rat: Effects of clonidine. Pharmacol Biochem Behav 1983; 18: 209–215.CrossRefGoogle Scholar
  207. 207.
    Miyamoto Y, Takemori AE. Sites of action of naloxone in precipitating withdrawal jumping in morphine-dependent mice: Investigations by the ED50 value and CNS content of naloxone. Drug Alcohol Depend 1993; 32: 163–167.PubMedCrossRefGoogle Scholar
  208. 208.
    Miyamoto Y, Takemori AE. Relative involvement of supraspinal and spinal mu opioid receptors in morphine dependence in mice. Life Sci 1993; 52: 1039–1044.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Rafael Maldonado
    • 1
  • Luis Stinus
    • 2
  • George F. Koob
    • 3
  1. 1.Pharmacochimie Moléculaire et StructuraleParisFrance
  2. 2.Université de Bordeaux IIBordeaux CédexFrance
  3. 3.The Scripps Research InstituteLa JollaUSA

Personalised recommendations